Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma
Cancer Letters · 2025-08 · 626 · 217774
DOI: 10.1016/j.canlet.2025.217774 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-08. Verfasst von Shuo Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Phosphofructokinase-2, Liver Neoplasms, Lipogenesis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Anhui Provincial Department of Education, Natural Science Foundation of Anhui Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is among the most aggressive malignancies, marked by high recurrence rates and limited treatment efficacy, especially in HBV-associated HCC (HBV-HCC). This subtype exhibits pronounced metabolic reprogramming, with lipid synthesis playing a pivotal role in driving tumor aggressiveness and therapeutic resistance. However, the molecular mechanisms underlying this metabolic shift remain unclear. In our study, analysis of the LIHC-TCGA database and comparisons between HCC tissues and adjacent peri-tumoral tissues revealed that 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4) is significantly upregulated in HBV-HCC. Moreover, elevated PFKFB4 expression correlates with poorer prognosis and unfavorable overall survival among HBV-HCC patients. Functional assays demonstrated that PFKFB4 promotes HCC proliferation by enhancing glycolysis and de novo lipid synthesis. Notably, PFKFB4 not only increases glycolytic flux but also upregulates sterol regulatory element-binding protein 1 (SREBP1) expression via its enzymatic activity. Mechanistically, PFKFB4 suppresses phosphorylated AMP-activated protein kinase (p-AMPK) through enhanced aerobic glycolysis, which in turn stimulates the level of SREBP1. Collectively, these findings position PFKFB4 as a critical mediator of metabolic reprogramming in HBV-HCC and a promising therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of C…
- Department of General Surgery, Key Laboratory of Hepatosplenic Surgery, Ministry of Education, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.
Förderung
- National Key Research and Development Program of China
- Anhui Provincial Department of Education
- Natural Science Foundation of Anhui Province
- National Natural Science Foundation of China
Zitieren
APA
Zhou, S., Liu, Y., Zhang, N., Sun, L., Ji, C., Cui, T., Chu, Q., Zhang, S., Wang, J., & Liu, L. (2025). Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma. Cancer Letters, 626, 217774. https://doi.org/10.1016/j.canlet.2025.217774
Vancouver
Zhou S, Liu Y, Zhang N, Sun L, Ji C, Cui T, et al. Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma. Cancer Letters. 2025;626:217774. doi:10.1016/j.canlet.2025.217774
BibTeX
@article{Zhou2025,
author = {Zhou, Shuo and Liu, Yao and Zhang, Ning and Sun, Linmao and Ji, Changyong and Cui, Tianming and Chu, Qi and Zhang, Shugeng and Wang, Jiabei and Liu, Lianxin},
title = {Glycolytic enzyme PFKFB4 governs lipolysis by promoting de novo lipogenesis to drive the progression of hepatocellular carcinoma},
journal = {Cancer Letters},
year = {2025},
volume = {626},
pages = {217774},
doi = {10.1016/j.canlet.2025.217774}
}
EUVIMED